Parafibromin is a putative tumor suppressor encoded by HRPT2, mutations in which have been implicated in the familial tumor syndrome hyperparathyroidism jaw tumor syndrome (HPT-JT), and sporadic parathyroid carcinoma. Recently, parafibromin has been shown to be an accessory factor for RNA polymerase II as part of the human Paf1 complex, suggesting, as has been shown for its yeast homologue (Cdc73), that it may have a role as an important regulator of transcription. Parafibromin has also been shown to interact with a histone methyltransferase complex that methylates histone H3 and to inhibit proliferation when overexpressed in mammalian cell lines. Despite these findings, the cellular localization of parafibromin has been controversial, with reports of both nuclear and nucleocytoplasmic localization. We have expressed wild-type and mutant parafibromin tagged with enhanced green fluorescent protein and have identified a functional bipartite nuclear localization signal (NLS) at residues 125-139 (nucleotides 373-417), KRAADEV-LAEAKKPR, that is evolutionarily conserved and critical for the nuclear localization of parafibromin. We have also shown that the C-terminal arm of this bipartite NLS plays the primary role in nuclear localization. In support of these findings, specific HRPT2 mutations identified in HPT-JT or sporadic parathyroid carcinoma predicted to truncate parafibromin upstream of or within this NLS disrupt nuclear localization.
Introduction
Hyperparathyroidism jaw tumor syndrome (HPT-JT; OMIM #145001) is characterized by aggressive benign, or in 15% of cases malignant, parathyroid tumors; fibro-osseous jaw tumors of the mandible or maxilla; and an increased risk of Wilms' tumors, renal hamartomas and/or renal cystic disease . The putative tumor suppressor gene HRPT2 that encodes the human protein parafibromin was recently identified and linked to HPT-JT (Carpten et al., 2002) . Germline predicted loss of function mutations in HRPT2 have been identified in approximately 60% of families with HPT-JT (Carpten et al., 2002; Howell et al., 2003) . Germline mutations have also been found in a small subset of patients with familial isolated hyperparathyroidism (FIHP; OMIM #145000) (Carpten et al., 2002; Howell et al., 2003; Simonds et al., 2004; Villablanca et al., 2004) and in a minority of patients with sporadic parathyroid carcinomas (Shattuck et al., 2003) .
Somatic HRPT2 mutations have been identified in the majority of sporadic parathyroid carcinomas (Howell et al., 2003; Shattuck et al., 2003) . Allelic loss of the wild-type allele, or point mutation of the second allele, has been reported in a subset of these tumors (Howell et al., 2003; Shattuck et al., 2003) . Further, reduced expression of parafibromin has been reported in parathyroid carcinoma (Tan et al., 2004) , and overexpression has been shown to inhibit cell proliferation (Woodard et al., 2004) . Taken together, these findings support a likely tumor suppressor function for HRPT2/ parafibromin.
HRPT2 has been isolated from cDNA libraries of parathyroid, kidney and bone tissue (Carpten et al., 2002) , and information from its Unigene Cluster (Hs.5722) suggests that it is ubiquitously expressed. Human parafibromin shares 32% identity and 54% similarity with the yeast homologue Cdc73, although no homologies to known protein domains are apparent (Carpten et al., 2002) . Cdc73 is part of the yeast RNA polymerase II/Paf1 complex that also contains Ctr9, Hpr1, Ccr4, Rtf1 and Leo1 (Betz et al., 2002) . This yeast complex localizes to the nucleus (Porter et al., 2005) and has been shown to be important for lipid and nucleic acid metabolism, histone methylation and cell cycle regulation (Betz et al., 2002; Hampsey and Reinberg, 2003) . A recent study has identified human homologues to members of the yeast Paf1 complex including hLeo1, hPaf1 and hCtr9, and show that parafibromin forms part of this complex (Rozenblatt-Rozen et al., 2005) .
Two studies of human parafibromin have recently reported nuclear localization of this protein (Tan et al., 2004; Rozenblatt-Rozen et al., 2005) , with a third reporting localization as nucleocytoplasmic (Woodard et al., 2004) ; however, a clearly functional nuclear localization signal (NLS) was not identified. In order to identify human parafibromin's NLS, we have fused parafibromin to enhanced green fluorescent protein (EGFP) and, using a series of deletion constructs and introduced point mutations, determined the site of a functional bipartite NLS.
Results

Localization of parafibromin fused to the C-terminus of EGFP
In human embryonic kidney (HEK293) cells transfected with pEGFP-C1-HRPT2, EGFP fluorescence overlaid with Hoechst-stained nuclei demonstrated that parafibromin fused to the C-terminus of EGFP was localized to the nucleus ( Figure 1a , upper panel). Identical results were obtained when parafibromin was fused to the N-terminus of EGFP (data not shown). Cells transfected with the EGFP-empty vector (pEGFP-C1) showed EGFP expression throughout both the cytoplasm and nucleus ( Figure 1a , lower panel). Nuclear localization of EGFP-parafibromin was confirmed in a number of different cell lines: glioblastoma (A172), colorectal (hCT116), breast (MCF7), osteosarcoma (MG63) and prostate (PC3) carcinoma (data not shown).
To ensure that full-length parafibromin fused to EGFP was being expressed, Western blot analysis using an anti-GFP antibody was carried out on cell extracts prepared from HEK293 cells transiently transfected with pEGFP-C1 or pEGFP-C1-HRPT2. Parafibromin is a 531 amino-acid protein previously shown by Western blot to be approximately 60 kDa in size (Woodard et al., 2004) . A protein of approximately 85 kDa was detected in cells transfected with pEGFP-C1-HRPT2, suggesting that full-length parafibromin was being expressed (Figure 1b) . A single band of approximately 31 kDa was detected in cells transfected with pEGFP-C1, reflecting expression of EGFP (27 kDa) and the multiple cloning site of this vector.
Identification of a functional bipartite NLS in parafibromin
It has been previously reported that parafibromin contains two putative NLS predicted at residues 76-92, RRAATENIPVVRRPDRK and 393-409, KKQGCQRENETLIQRRK (Tan et al., 2004) . To investigate whether either of these NLS were functional, a number of deletion constructs in which different fragments of HRPT2 were fused to the C-terminus of EGFP were generated by restriction digestion (Figure 2a) . A C-terminal fragment (Figure 2a , pEGFP-CTermini) of parafibromin did not localize EGFP to the nucleus (Figure 2b ), suggesting that the predicted NLS at residues 393-409 was not functional. In contrast, an N-terminal fragment (Figure 2a , pEGFP-C1-NTermini) of parafibromin localized EGFP to the nucleus (Figure 2b ). Further, expression of the first 53 residues of parafibromin ( Figure 2a , pEGFP-C1-NTermini2), did not localize EGFP to the nucleus (Figure 2b ). Localization data from the above three constructs indicated that the sequence mediating nuclear localization of parafibromin resides between residues 53 and 194. The functionality of the other predicted NLS, located at residues 76-92, was excluded by localization data obtained from pEGFP-C1-del161-289 (Figure 2a ) in which residues 54-96 had been deleted, but retained nuclear localization of the EGFP-parafibromin fusion protein (Figure 2b ). The nonfunctionality of this NLS was confirmed by two constructs in which the two basic amino acids of the N-terminal arm of this NLS (RR) were mutated to serine or the two basic amino acids in the C-terminal arm (RK) were mutated to serine and threonine by site-directed mutagenesis. The nuclear localization of EGFP-parafibromin was not disrupted by these mutations (data not shown). The localization data from the four deletion constructs described above indicated that the sequence mediating nuclear localization lay between residues 96 and 194 (Figure 2a) .
Examination of the parafibromin amino-acid sequence between residues 96 and 194 revealed the presence of an alternative NLS. Although not identified by motifscan, http://myhits.isb-sib.ch/cgi-bin/motif_scan, it is similar to many bipartite NLS that have been reported , being composed of two basic amino acids separated by nine amino acids from a small cluster of three basic amino acids that is interrupted by a proline (K R A A D E V L A E A K K P R). Site-directed mutagenesis was used to confirm the functionality of this NLS, and further, to determine the role of each of the two arms of the bipartite NLS in nuclear localization.
Two basic amino acids within the N-terminal arm of the NLS (pEGFP-C1-Mutant1, Figure 3a ) or the C-terminal cluster of the NLS (pEGFP-C1-Mutant2, Figure 3a ) were mutated to asparagines, consistent with previous reports mutating basic amino acids in putative NLSs to neutral amino acids to disrupt nuclear localization (Robbins et al., 1991; Jans et al., 1997; Linder et al., 2000) .
In a final construct, mutation of both arms of the putative NLS was included in full-length HRPT2 fused to the C-terminus of EGFP (pEGFP-C1-Mutant3, Figure 3a ). Fluorescence microscopy revealed that mutation of the N-terminal arm of the NLS disrupted nuclear localization to a small degree with EGFP primarily localized to the nucleus. In contrast, disruption of the C-terminal arm of the NLS more strongly disrupted nuclear localization. When both arms were mutated, parafibromin was primarily localized to the cytoplasm ( Figure 3b ). To confirm the functionality of this NLS, the sequence encoding the NLS was fused to EGFP (pEGFP-C1-NLS). In HEK293 cells transfected with this construct, EGFP fluorescence overlaid with Hoechst nuclear staining demonstrated that this NLS alone could localize EGFP to the nucleus (Figure 3c ). The results described above demonstrate that the NLS identified at residues 125-139 is functional and mediates nuclear localization of EGFP-parafibromin. Further, the C-terminal arm of this NLS plays the primary role in this localization.
A number of HRPT2 mutations associated with parathyroid tumorigenesis disrupt nuclear localization of parafibromin A number of HRPT2 mutations have been identified in patients with HPT-JT, FIHP and sporadic parathyroid carcinomas. All of these mutations except one (c.191T-C, (L64P)) (Carpten et al., 2002) generate premature translational stop codons, which are predicted to result in the expression of truncated parafibromin. Further, two of these mutations occur in the functional NLS described above (c.373insA and c.406A-T (L136X) (Carpten et al., 2002; Shattuck et al., 2003) . Five of these mutations, the three listed above and one that occurs upstream (c.226C-T (R76X) (Shattuck et al., 2003) and another downstream (c.636delT) (Carpten et al., 2002) of the functional NLS, were introduced by site-directed mutagenesis into HRPT2 fused to the C-terminus of EGFP to generate five constructs (Tables 1 and 2 ). It should be noted that two of these mutations (c.373insA and c.636delT) are frameshift mutations and result in the expression of four or five nonsense amino acids, respectively, after the frameshift occurs. Amino acids that are important for nuclear import or export such as an arginine, introduced following c.373insA, or two leucines and an arginine, introduced following c.636delT, are unlikely to influence the localization of proteins expressed from the constructs described above, as more than one or two amino acids are generally required to mediate nuclear import or export.
Western blot analysis of HEK293 cells expressing each of these constructs was carried out, and although different mutants were expressed at different levels, which may reflect changes in either mRNA or protein stability, all truncating mutations resulted in the expression of an EGFP fusion protein of predicted molecular weight (data not shown). EGFP fluorescence overlaid with Hoechst-stained nuclei of HEK293 cells transfected with these constructs revealed that c.191T-C does not interfere with the nuclear localization of EGFP-parafibromin (Figure 4) . In contrast, introduction of mutation c.226C-T, which results in the expression of the N-terminal 75 residues of parafibromin and therefore does not contain the NLS, was localized primarily to the cytoplasm (Figure 4) . EGFP-parafibromin in which c.373insA had been introduced was localized throughout both the nucleus and the cytoplasm. c.406A-T mutated EGFP-parafibromin also showed both nuclear and cytoplasmic localization, with increased localization in the nucleus (Figure 4) .
These data are consistent with that shown earlier. The mutant c.373insA allows expression of parafibromin up to the second amino acid of the functional NLS. Thus, localization is totally disrupted in this construct. The mutant c.406A-T is predicted to prematurely truncate parafibromin prior to the C-terminal arm of the identified NLS, shown earlier to be the dominant arm of the bipartite NLS in directing nuclear localization (Figure 3) . Thus, this construct contains the N-terminal arm of the functional NLS that we have identified and can, to a small degree, increase localization to the nucleus as shown. The final mutant, c.636delT, demonstrated a nuclear localization as expected since this mutation results in truncation downstream of the functional NLS (Figure 4) .
The functional NLS of parafibromin is conserved in parafibromin homologues
HRPT2 is an evolutionarily conserved protein that has Mus musculus, Rattus norvegicus, Drosophila melanogaster and Caenorhabditis elegans homologues. To examine whether the functional NLS that we have identified is Figure 4 The affect of HRPT2 mutation on the cellular localization of EGFP-parafibromin. From left, representative (three separate experiments) fluorescent microscopy images of EGFP fluorescence (green), Hoechst 33258-stained nuclear fluorescence (blue) and a merge of these two images are shown for HEK293 cells transfected with five different pEGFP constructs containing HRPT2 that was mutated at five different sites, which are mutated in patients with HPT-JT, FIHP or sporadic parathyroid carcinomas conserved in these homologues, alignments of each of these proteins were carried out using Homologene (National Centre for Biotechnology Information, http://www.ncbi.nlm.nih.gov/). Basic amino acids in the C-terminal arm of the functional NLS were shown to be conserved in all species, while the N-terminal was conserved in all but the C. elegans sequence ( Figure 5 ).
Discussion
The fusion of proteins of interest to EGFP has proved a powerful tool in dissecting motifs within gene and protein sequences that mediate cellular localization (Linder et al., 2000; van Koningsbruggen et al., 2004) . We have used this strategy and generated a number of fusion proteins in which parafibromin, fragments of parafibromin or mutated versions of parafibromin, were fused to EGFP, which have allowed us to identify a functional bipartite NLS at residues 125-139 within human parafibromin. Further, we have shown that mutations predicted to prematurely truncate parafibromin located upstream or within this NLS that are known to occur in association with parathyroid tumorigenesis disrupt nuclear localization of this protein. The identification of a functional bipartite NLS within parafibromin provides strong evidence that parafibromin is a nuclear protein.
Parafibromin's NLS structure of two basic amino acids separated by nine amino acids followed by another cluster of basic amino acids is similar to many that have been identified in other proteins from a diverse number of species (Robbins et al., 1991; Jans et al., 1997; Linder et al., 2000) . In many instances, mutation of one arm of the NLS is sufficient to disrupt nuclear localization (Robbins et al., 1991; Jans et al., 1997; Linder et al., 2000) . In contrast, the arms of the human parafibromin NLS identified in this study differentially mediated nuclear localization, with the C-terminal arm more strongly directing nuclear localization. Similar results have been obtained for NLSs identified in IGFBP-3 and IGFBP-5 that are made up of three clusters of basic amino acids (Schedlich et al., 2000) .
A recent report has suggested that the amino acids 136-139 may be the functional parafibromin NLS (Rozenblatt-Rozen et al., 2005) . From data obtained in the current study, residues 136-139 make up the C-terminal arm of a functional bipartite NLS that is made up of amino acids 125-139. Mutation of the Nterminal arm, as well as data obtained from the mutation c.406A-T, suggests that while the N-terminal arm plays only a minor role, it can affect EGFPparafibromin localization.
Examination of parafibromin homologues M. musculus, R. norvegicus, D. melanogaster and C. elegans show conservation of basic amino acids in the C-terminal arm of the functional NLS. The N-terminal arm is conserved in all species except C. elegans ( Figure 5 ). As would be expected, the sequence diverges in the more evolutionarily distant organisms D. melanogaster and C. elegans. The D. melanogaster sequence contains an alanine in the C-terminal arm, which is a proline in the other organisms. Further, the number of amino acids that separate the N-and C-terminal arms of the NLS is four amino acids longer in D. melanogaster. In the most divergent sequence, C. elegans, the N-terminal arm is not present, suggesting that the C-terminal arm, shown to be the major sequence responsible for nuclear localization of human parafibromin, may be sufficient to mediate localization in this species as a nonbipartite NLS. Finally, the conserved human NLS is located in the N-terminal region of parafibromin that does not exist in the yeast homologue of this protein, cdc73. Since cdc73 has been shown to be involved in nuclear processes in yeast, cdc73 may be localized to yeast nuclei via an alternative NLS signal that is not present in human parafibromin or via a mechanism that does not require an NLS.
A nuclear localization for human parafibromin is consistent with a role for this protein as an accessory factor for RNA polymerase II as part of the Paf1 complex (Rozenblatt-Rozen et al., 2005) . The finding that parafibromin blocks expression of the cell cycle regulator cyclin D1 (Woodard et al., 2004) , previously known to be overexpressed in parathyroid tumors (Hsi et al., 1996) , is also consistent with a nuclear localization for this protein. A recent report suggesting that parafibromin's location may in fact be 'nucleocytoplasmic' (Woodard et al., 2004) raises the possibility that parafibromin may be a nuclear protein with the ability to be transported to the cytoplasm under certain conditions. A number of proteins that regulate transcription such as Ikb-a and p53 can be shuttled between the cytoplasmic and nuclear compartments via various regulatory mechanisms and it cannot be discounted that similar shuttling of parafibromin may occur. Proteins such as Ikb-a and p53 contain nuclear export sequences (NES), which mediate their export from the nucleus (Stommel et al., 1999; Henderson and Eleftheriou, 2000; Huang and Miyamoto, 2001 ). Examination of Figure 5 The C-terminal arm of the functional NLS identified from residues 125 to 139 is highly conserved. A sequence alignment of the functional NLS identified within human parafibromin with that of M. musculus, R. norvegicus, D. melanogaster and C. elegans. Conserved amino acids within the functional NLS are shown in bold and shaded gray and residue numbers corresponding to the human sequence are also shown parafibromin has revealed two putative leucine-rich regions, which may function as NESs. Studies are currently underway to determine the functionality of these putative NESs in parafibromin.
Materials and methods
Cloning of HRPT2
HRPT2 was PCR amplified using AccuPrime Pfx (Invitrogen Australia Pty Ltd, Vic., Australia) from HEK293 cDNA using the primers 5 0 -TAATCTCGAGCTATGGCGGACGTGCT TAGCGT-3 0 and 5 0 -TGCTCTCGAGTCTCCTTGAAGCA CAAAGCAT-3 0 and the following PCR cycles: denaturation at 951C for 2 min and then 35 cycles of 951C for 1 min, annealing at 581C for 1 min, extension at 681C for 2 min followed by a final extension at 721C for 10 min. PCR amplified HRPT2 was then cloned into the XhoI/HindIII sites of pEGFP-C1 to produce pEGFP-C1-HRPT2 (Table 1) . Alternatively, HRPT2 was amplified as described above using 5 0 -TAATGGTACCGGCGACAAGA GAAGAAGGAG-3 0 and 5 0 -TGCTCCCGGGAGAATCT CAAGTGCGATTTAT-3 0 and cloned into the KpnI/XmaI sites of pEGFP-N1 to produce pEGFP-N1-HRPT2. The PCR fidelity of HRPT2 amplification was confirmed by complete sequencing of HRPT2 in both constructs, which also demonstrated that HRPT2 was in frame with EGFP (Supamac, Sydney University, NSW, Australia).
HRPT2 deletion constructs
In order to facilitate mapping of a potential NLS site, four different constructs were generated by restriction digestion and cloning to allow expression of various fragments of HRPT2 fused to the C-terminus of EGFP (Table 1) . In the first, pEGFP-C1-HRPT2 was digested with BglII to remove an N-terminal fragment, therefore allowing expression of the C-terminal 1014 nucleotides of HRPT2 (residues 194-531 of parafibromin) (pEGFP-C1-CTermini). In the second, pEGFP-C1-HRPT2 was digested with BamHI to excise a C-terminal fragment, therefore allowing expression of the N-terminal 833 nucleotides of HRPT2 (residues 1-278 of parafibromin) (pEGFP-C1-NTermini). A third construct was generated using an ScaI and EcoRV digest followed by blunt-end ligation of pEGFP-C1-HRPT2. Blunt-end ligation resulted in inadvertent deletion of two nucleotides, c.290-291, that created a frame shift giving rise to a premature stop codon. This construct therefore allowed expression of the N-terminal 159 nucleotides of HRPT2 (residues 1-53 of parafibromin) fused to EGFP (pEGFP-C1-NTermini2). A fourth construct was generated by a double digest using ScaI and EcoRV to remove a 129 nucleotide fragment from c.161-289 of HRPT2 (residues 54-96 of parafibromin) (pEGFP-C1-del161-289).
A final construct was generated using PCR. The putative NLS identified between nucleotides 373 and 417 of HRPT2 (residues 125-139 of parafibromin) was amplified with the primers, 5 0 -TAATCTCGAGCTAAACGAGCTGCAGAT GAAGT-3 0 and 5 0 -TGCTAAGCTTGTCGTGGTTTCTTT GCTTCTG-3 0 and cloned into the XhoI/HindIII site of pEGFP-C1 to generate pEGFP-NLS.
Site-directed mutagenesis
Site-directed mutagenesis was carried out on pEGFP-C1-HRPT2 to convert two basic amino acids in the N (residues 125 and 126) or C-terminal (residues 136 and 137) arms of the putative NLS identified from residues 125-139 to the neutral amino-acid asparagine. Site-directed mutagenesis was also used to mutate the putative NLS that has been reported previously (residues 76-92) (Tan et al., 2004) . Two basic amino acids of the N-terminal arm of this NLS (RR) were mutated to serine or the two basic amino acids in the C-terminal arm (RK) were mutated to serine and threonine. Mutagenesis was carried out using the QuickChange II site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions. Constructs and mutagenesis primers are described in Tables 1 and 2 .
Five mutations that had previously been identified in patients with HPT-JT, FIHP or sporadic parathyroid carcinomas were also introduced individually into pEGFP-C1-HRPT2 using site-directed mutagenesis to generate five constructs (Tables 1 and 2 ). HRPT2 was fully sequenced in all of the above constructs to confirm sequence integrity (Supamac, Sydney University, NSW, Australia). Table 2 )
Cell culture HEK293 and MG63 cell lines were cultured in DMEM (GIBCO, Invitrogen Australia Pty Ltd, Vic., Australia) supplemented with 10% FCS (Trace Scientific Ltd, Vic., Australia), while A172, HCT116, MCF7 and PC3 cell lines were cultured in RPMI supplemented with 10% FCS. All cells were incubated at 371C in a humidified 5% CO 2 atmosphere.
Transient transfections
At 24 h prior to transfection, 6 Â 10 4 cells were seeded into single wells of 24-well culture dishes. Cells were transfected with 1 mg of DNA using Fugene 6 according to the manufacturer's instructions (Roche Diagnostics Australia Pty Ltd, NSW, Australia).
Immunofluorescent microscopy
At 48 h after transfection, cells were stained with Hoechst 33258 (10 mg/ml) (Sigma-Aldrich Australia, NSW, Australia) at 371C for 30 min. EGFP and Hoechst fluorescence were visualized using an Olympus (IX70) fluorescent microscope and images were captured with a Spot digital camera (RTke, Diagnostic instruments, MI, USA).
Western blot analysis
Cell lysates containing 20 mg of protein were loaded onto 12% PAGE and electrophoresed at 25 A for 45 min (Bio-Rad Laboratories Pty Ltd, NSW, Australia). Proteins were then electrophoretically transferred to nitrocellulose (Amersham Biosciences Pty Ltd, NSW, Australia) for 1.5 h at 25 A. Nonspecific protein binding sites were then blocked by a 1 h incubation in blocking buffer (40 mM Tris (pH 7.4), 0.1% Tween-20, 5% skim milk). The nitrocellulose membrane was incubated with a monoclonal anti-GFP antibody (diluted 1/5000 in 40 mM Tris, 0.1% Tween-20, 5% skim milk) (Roche Diagnostics Australia Pty Ltd, NSW, Australia) for 1 h and subsequently rinsed in wash buffer (3 Â 5 min in 20 mM Tris (pH 7.4), 0.1% Tween-20, 150 mM NaCl). Incubation with an anti-mouse immunoglobulin HRP-conjugated secondary antibody (Amersham Biosciences Pty Ltd, NSW, Australia) (diluted 1/2500 in 40 mM Tris, 0.1% Tween-20, 5% skim milk) was then carried out for 1 h. The nitrocellulose was rinsed in wash buffer as above and developed using enhanced chemiluminescence (Pierce Biotechnology Inc., IL, USA) as per the manufacturer's instructions.
